ReviewAnnals of neurology2026
Back Again to the Future: A New Era for Cerebroprotection.
Review in Annals of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.Neurology · 2026Article
- Bruceine E, a natural quassinoid from Brucea javanica, inhibits PARthanatos via targeting PARP1 in ischemic stroke.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
In multiple disease areas, neurology has failed to translate promising treatments from positive preclinical studies to successful clinical trial results. Despite this history, we persist in testing new, putative neuroprotectants using the same concepts, approaches, and methods without much modification. Recent novel data and new concepts offer an opportunity to break with past doctrine decisively, and open a new era of different approaches, methods, and strategies for studying future protections for brain injury. Cerebroprotection is a fresh framework for designing neurological therapy that targets glia and vascular cells, in addition to neurons. ANN NEUROL 2026;99:19-34.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.